Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 44,857 shares of the biotechnology company’s stock, valued at approximately $2,560,000.
Several other institutional investors have also made changes to their positions in BIVV. Advisors Asset Management Inc. acquired a new stake in shares of Bioverativ during the third quarter valued at about $137,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Bioverativ during the third quarter valued at about $186,000. Canada Pension Plan Investment Board acquired a new stake in shares of Bioverativ during the third quarter valued at about $194,000. ACG Wealth acquired a new stake in shares of Bioverativ during the third quarter valued at about $205,000. Finally, Pinnacle Associates Ltd. acquired a new stake in shares of Bioverativ during the third quarter valued at about $217,000. Institutional investors own 95.23% of the company’s stock.
Several analysts have recently weighed in on the company. Piper Jaffray Companies restated an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 target price for the company in a research note on Thursday, October 19th. Jefferies Group restated a “buy” rating and set a $70.00 target price (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Morgan Stanley restated an “underweight” rating and set a $47.00 target price (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Finally, Evercore ISI assumed coverage on Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Bioverativ currently has a consensus rating of “Hold” and an average price target of $60.93.
Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. Bioverativ’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities research analysts predict that Bioverativ Inc will post 2.45 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Skandinaviska Enskilda Banken AB publ Buys Shares of 44,857 Bioverativ Inc (BIVV)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/06/skandinaviska-enskilda-banken-ab-publ-buys-shares-of-44857-bioverativ-inc-bivv.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.